top of page

beLAB 2122: Translational BRIDGE partnership to develop bifunctional degrader

A oncology project from Goethe University was now chosen for funding within the beLAB2122 BRIDGE partnership. On the academic side, the project emerges from PROXIDRUGS activities in Ivan Đikić's lab. It aims to develop bifunctional molecules that interfere with RNA splicing, paving the road to a first-in-class cancer treatment. beLAB2122 provides funding, technology platforms and mentoring to validate academically developed concepts for new therapeutics and technologies. The translational collaboration BRIDGE was founded in April 2021 between Evotec and Bristol Myers Squibb. The project from Goethe University is the second project selected for funding.

Read more in press releases by EVOTEC SE and Goethe University.


bottom of page